-
Launch One Acquisition Corp appoints Daniel Clifford Rogers to board, replacing Risa Stack as audit committee chair
Dr. Risa Stack resigned from the Board and as audit committee chair, effective June 2, 2026; no disagreement cited.
-
Launch One Acquisition secures up to $1M working capital note from sponsor; 51% founder shares pledged as collateral
Note allows up to $1,000,000 in loans; original issue discount of 20% yields $1,250,000 principal amount.
-
Launch One Acquisition terminates business combination with Minovia Therapeutics
Mutual termination effective Jan 30, 2026; BCA originally signed June 25, 2025 and amended four times.
-
Launch One SPAC to acquire Minovia Therapeutics in $180M de-SPAC merger
Total consideration $180M in Pubco shares, plus $57.5M earnout tied to stock price ≥$11.50 or phase 3 trial start.
-
Launch One Acquisition Corp. to combine with Minovia Therapeutics at $180M valuation, targeting Q4 2025 close
Minovia pre-money valuation of $180M; equity holders eligible for up to $57.5M earnout based on milestones.
-
Launch One Acquisition announces separate trading of shares and warrants from September 3, 2024
Holders of units (LPAAU) may elect to separate into Class A shares (LPAA) and warrants (LPAAW) starting September 3, 2024.
-
Launch One Acquisition Corp. completes $230M IPO and $6M private placement
Sold 23M units at $10.00 each (including full over-allotment of 3M units) for gross proceeds of $230M.
-
Launch One Acquisition Corp. closes $230M IPO, trust funded
Closed IPO of 23,000,000 units at $10.00/unit, gross proceeds $230M; includes full over-allotment exercise.